Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

Inclusion Criteria:

• Eligible female non-pregnant participants who are either not of child-bearingpotential or willing to use adequate contraception during the trial

• Males must be willing to practice abstinence or utilize adequate contraception fromdosing day to at least 7 days post-dose

• For women of childbearing potential, the participant should have a negative serumpregnancy test at screening, and agrees to one of the following acceptablecontraceptive methods used consistently and correctly i.e. abstinence, oralcontraceptive either combined or progesterone alone; injectable progesterone,implants of levonorgestrel, estrogenic vaginal ring, percutaneous contraceptivepatches, IUD device or system or male partner sterilization

• Men will not donate sperm during the study and for 1 month following the last doseof study drug.

• Participants who are capable of directly providing informed consent and who cancomply with the requirements and restrictions required by the protocol

• Adequate venous access sufficient to allow blood sampling per protocol requirements

Exclusion Criteria:

• Participants positive for COVID-19 at the time of dosing

• Recent donation or loss of blood or plasma: 100 mL to 499 mL within 30 days prior tothe initial dose of the study medication; or more than 499 mL within 56 days priorto the initial dose of study medication

• Non-steroidal anti-inflammatory (NSAID) use within 3 days of MB-102 dosing

• The participant has participated in a clinical trial and has received aninvestigational product within the following time ranges: prior to the first dosingday in the current study: either 30 days or 5 half-lives of the investigationalproduct (whichever duration is longer).

• History of skin sensitivity to adhesives (e.g. Band-Aids, surgical tape)

• History of severe allergic hypersensitivity reactions (unacceptable adverse events)or anaphylactoid reaction to any allergen including drugs, MB-102 or other relatedproducts (intolerance to a drug is not considered a drug allergy).

• Any characteristics which, in the opinion of the investigator, makes the participanta poor candidate for participation in the clinical trial

• Significant scaring, tattoos or alterations in pigmentation on the sternum or othersensor location testing areas that would alter sensor readings versus other areas ofthe skin

• Use of tanning sprays, tanning products etc. on the upper chest within 2 weeks ofdosing day

• Use make-up, lotions, Vaseline or other products on the area of the upper chest onthe day prior to or the day of dosing

• Any serious or uncontrolled medical disorder, active infection, physical examfinding, laboratory finding, or psychiatric condition that in the opinion of theinvestigator would limit the participant's ability to complete study requirements ormay put the participant at increased risk or compromise the interpretability ofstudy results.

• Currently receiving dialysis

• Currently anuric

• Positive serum pregnancy test

• Participants with an eGFR > 120 mL/min/1.73m^2